These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8353949)

  • 61. Molecular species of phospholipids with very long chain fatty acids in skin fibroblasts of Zellweger syndrome.
    Hama K; Nagai T; Nishizawa C; Ikeda K; Morita M; Satoh N; Nakanishi H; Imanaka T; Shimozawa N; Taguchi R; Inoue K; Yokoyama K
    Lipids; 2013 Dec; 48(12):1253-67. PubMed ID: 24122089
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A comparison of erythrocytes, lymphocytes and blood plasma as samples in fatty acid analysis for the diagnosis of adrenoleukodystrophy.
    Antoku Y; Ohtsuka Y; Nagara H; Sakai T; Tsukamoto K; Iwashita H; Goto I
    J Neurol Sci; 1989 Dec; 94(1-3):193-200. PubMed ID: 2614467
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Determination of C20-C30 fatty acids by reversed-phase chromatographic techniques: an efficient method to quantitate minor fatty acids in serum of patients with adrenoleukodystrophy.
    Alberghina M; Fiumara A; Pavone L; Giuffrida AM
    Neurochem Res; 1984 Dec; 9(12):1719-27. PubMed ID: 6531070
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders.
    Jaspers YRJ; Ferdinandusse S; Dijkstra IME; Barendsen RW; van Lenthe H; Kulik W; Engelen M; Goorden SMI; Vaz FM; Kemp S
    Front Cell Dev Biol; 2020; 8():690. PubMed ID: 32903870
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.
    Watkins PA; Naidu S; Moser HW
    J Inherit Metab Dis; 1987; 10 Suppl 1():46-53. PubMed ID: 3119941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. X-linked Adrenoleukodystrophy, The Tunisian Experience.
    Nasrallah F; Kraoua I; Zidi W; Omar S; Sanhaji H; Feki M; Ben Youssef IT; Kaabachi N
    Clin Lab; 2015; 61(10):1531-6. PubMed ID: 26642716
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum very long chain fatty acid pattern in Zellweger syndrome.
    Bakkeren JA; Monnens LA; Trijbels JM; Maas JM
    Clin Chim Acta; 1984 Apr; 138(3):325-31. PubMed ID: 6723067
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty acids and their use in prenatal diagnosis.
    Moser AE; Singh I; Brown FR; Solish GI; Kelley RI; Benke PJ; Moser HW
    N Engl J Med; 1984 May; 310(18):1141-6. PubMed ID: 6709009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Polarizing inclusions in some organs of children with congenital peroxisomal diseases (Zellweger's, Refsum's, chondrodysplasia punctata (rhizomelic form), X-linked adrenoleukodystrophy).
    Kerckaert I; Dingemans KP; Heymans HS; Vamecq J; Roels F
    J Inherit Metab Dis; 1988; 11(4):372-86. PubMed ID: 2468818
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy.
    Natarajan A; Christopher R; Netravathi M; Bhat M; Chandra SR
    Clin Chim Acta; 2018 Oct; 485():305-310. PubMed ID: 30018013
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cyclooxygenase pathway in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin.
    Malle E; Leis HJ; Steinmetz A; Paschke E; Hoefler G
    Clin Chim Acta; 1993 Aug; 217(2):205-12. PubMed ID: 8261630
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A rapid screening procedure for the diagnosis of peroxisomal disorders: quantification of very long-chain fatty acids, as dimethylaminoethyl esters, in plasma and blood spots, by electrospray tandem mass spectrometry.
    Johnson DW
    J Inherit Metab Dis; 2000 Jul; 23(5):475-86. PubMed ID: 10947202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders.
    Klouwer FC; Huffnagel IC; Ferdinandusse S; Waterham HR; Wanders RJ; Engelen M; Poll-The BT
    Neuropediatrics; 2016 Aug; 47(4):205-20. PubMed ID: 27089543
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peroxisomal beta-oxidation enzyme proteins in adrenoleukodystrophy: distinction between X-linked adrenoleukodystrophy and neonatal adrenoleukodystrophy.
    Chen WW; Watkins PA; Osumi T; Hashimoto T; Moser HW
    Proc Natl Acad Sci U S A; 1987 Mar; 84(5):1425-8. PubMed ID: 3469675
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diagnosis of peroxisomal disorders with neurological involvement.
    Molzer B
    Padiatr Padol; 1993; 28(1):43-8. PubMed ID: 8446428
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
    Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
    Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rhizomelic chondrodysplasia punctata: biochemical studies of peroxisomes isolated from cultured skin fibroblasts.
    Singh I; Lazo O; Contreras M; Stanley W; Hashimoto T
    Arch Biochem Biophys; 1991 Apr; 286(1):277-83. PubMed ID: 1680308
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A novel method for determining peroxisomal fatty acid β-oxidation.
    Morita M; Matsumoto S; Okazaki A; Tomita K; Watanabe S; Kawaguchi K; Minato D; Matsuya Y; Shimozawa N; Imanaka T
    J Inherit Metab Dis; 2016 Sep; 39(5):725-731. PubMed ID: 27324171
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Peroxisomes and neurologic diseases].
    Sereni C; Paturneau-Jouas M
    Rev Neurol (Paris); 1989; 145(5):341-9. PubMed ID: 2472665
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders.
    Klouwer FCC; Ferdinandusse S; van Lenthe H; Kulik W; Wanders RJA; Poll-The BT; Waterham HR; Vaz FM
    J Inherit Metab Dis; 2017 Nov; 40(6):875-881. PubMed ID: 28677031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.